Stephen J. Kanes's most recent trade in Sage Therapeutics Inc was a trade of 3,800 Common Stock done . Disclosure was reported to the exchange on Oct. 19, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc | Stephen J. Kanes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2021 | 3,800 | 14,591 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Stephen J. Kanes | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.29 per share. | 19 Oct 2021 | 1,120 | 13,471 (0%) | 0% | 40.3 | 45,125 | Common Stock |
| Sage Therapeutics Inc | Stephen J. Kanes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 3,500 | 11,792 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Stephen J. Kanes | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.80 per share. | 15 Jun 2021 | 1,001 | 10,791 (0%) | 0% | 58.8 | 58,859 | Common Stock |
| Sage Therapeutics Inc | Stephen J. Kanes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) |